X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs LUPIN - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA LUPIN ASTRAZENECA PHARMA/
LUPIN
 
P/E (TTM) x 61.1 47.1 129.8% View Chart
P/BV x 17.2 2.4 713.2% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   LUPIN
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
LUPIN
Mar-19
ASTRAZENECA PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs1,278986 129.6%   
Low Rs883720 122.5%   
Sales per share (Unadj.) Rs228.4369.5 61.8%  
Earnings per share (Unadj.) Rs10.413.4 77.3%  
Cash flow per share (Unadj.) Rs16.337.4 43.5%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs98.8303.7 32.5%  
Shares outstanding (eoy) m25.00452.49 5.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.72.3 204.8%   
Avg P/E ratio x104.263.6 163.8%  
P/CF ratio (eoy) x66.422.8 291.1%  
Price / Book Value ratio x10.92.8 389.3%  
Dividend payout %00-   
Avg Mkt Cap Rs m27,008386,064 7.0%   
No. of employees `0001.417.7 7.7%   
Total wages/salary Rs m1,53531,513 4.9%   
Avg. sales/employee Rs Th4,210.99,453.8 44.5%   
Avg. wages/employee Rs Th1,132.21,782.0 63.5%   
Avg. net profit/employee Rs Th191.1343.0 55.7%   
INCOME DATA
Net Sales Rs m5,710167,182 3.4%  
Other income Rs m1233,640 3.4%   
Total revenues Rs m5,833170,822 3.4%   
Gross profit Rs m46328,822 1.6%  
Depreciation Rs m14710,850 1.4%   
Interest Rs m03,078 0.0%   
Profit before tax Rs m43818,534 2.4%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m0-3,400 0.0%   
Tax Rs m1799,017 2.0%   
Profit after tax Rs m2596,066 4.3%  
Gross profit margin %8.117.2 47.0%  
Effective tax rate %40.848.7 84.0%   
Net profit margin %4.53.6 125.1%  
BALANCE SHEET DATA
Current assets Rs m3,209138,536 2.3%   
Current liabilities Rs m2,07061,299 3.4%   
Net working cap to sales %20.046.2 43.2%  
Current ratio x1.62.3 68.6%  
Inventory Days Days7284 86.3%  
Debtors Days Days35112 31.1%  
Net fixed assets Rs m790127,516 0.6%   
Share capital Rs m50905 5.5%   
"Free" reserves Rs m2,419136,517 1.8%   
Net worth Rs m2,469137,422 1.8%   
Long term debt Rs m066,417 0.0%   
Total assets Rs m4,605279,494 1.6%  
Interest coverage xNM7.0-  
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x1.20.6 207.3%   
Return on assets %5.63.3 172.0%  
Return on equity %10.54.4 237.7%  
Return on capital %17.78.9 199.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30059,414 0.5%   
Fx outflow Rs m2,01522,282 9.0%   
Net fx Rs m-1,71537,132 -4.6%   
CASH FLOW
From Operations Rs m8816,660 0.5%  
From Investments Rs m-94-32,825 0.3%  
From Financial Activity Rs mNA7,441 0.0%  
Net Cashflow Rs m-6-8,724 0.1%  

Share Holding

Indian Promoters % 0.0 46.6 -  
Foreign collaborators % 75.0 0.2 37,500.0%  
Indian inst/Mut Fund % 0.3 11.3 2.7%  
FIIs % 15.7 31.9 49.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.1 90.1%  
Shareholders   12,856 98,259 13.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   ABBOTT INDIA  ALKEM LABORATORIES  AJANTA PHARMA  PIRAMAL ENTERPRISES  ALEMBIC PHARMA  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Witness Selling, Passenger Vehicles Sales Data, and Top Cues in Focus Today(Pre-Open)

India share markets witnessed selling pressure yesterday and ended their session deep in the red. At the closing bell yesterday, the BSE Sensex stood lower by 267 points (down 0.7%).

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Super investor Pulak Prasad is Buying Stocks Big Time...and You Should Too(The 5 Minute Wrapup)

Aug 9, 2019

Here's why the relentless correction in the Indian stock markets has not unnerved the big investors.

Interest Rates Are Low. Buy Solid Dividend Stocks Instead(The 5 Minute Wrapup)

Aug 13, 2019

The dividends paid by these stocks are helpful when interest rates are falling.

Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

Qatar is Rearing Cows...this is Good News for India

Aug 9, 2019

Qatar has turned around after the Saudi embargo. This is good news for India.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Aug 21, 2019 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - CIPLA COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS